PlainRecalls
FDA Drug Moderate Class II Terminated

buPROPrion Hydrochloride Extended-Release Tablets, USP (SR) 150 mg, 60 Tablets, Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ, Manufactured by: Sun Pharmaceutical Industries Limited, Gujrat, India, NDC 47335-737-86

Reported: May 31, 2023 Initiated: May 9, 2023 #D-0761-2023

Product Description

buPROPrion Hydrochloride Extended-Release Tablets, USP (SR) 150 mg, 60 Tablets, Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ, Manufactured by: Sun Pharmaceutical Industries Limited, Gujrat, India, NDC 47335-737-86

Reason for Recall

Failed Dissolution Specifications; during stability testing

Details

Units Affected
5,344 Bottles
Distribution
Nationwide in the U.S.A
Location
Princeton, NJ

Frequently Asked Questions

What product was recalled?
buPROPrion Hydrochloride Extended-Release Tablets, USP (SR) 150 mg, 60 Tablets, Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ, Manufactured by: Sun Pharmaceutical Industries Limited, Gujrat, India, NDC 47335-737-86. Recalled by SUN PHARMACEUTICAL INDUSTRIES INC. Units affected: 5,344 Bottles.
Why was this product recalled?
Failed Dissolution Specifications; during stability testing
Which agency issued this recall?
This recall was issued by the FDA Drug on May 31, 2023. Severity: Moderate. Recall number: D-0761-2023.